Psoriasis

Advances in biologics and systemics have reshaped the lives of patients with psoriasis, offering clearer skin and joint protection.

Roundtable participants agreed the art of psoriasis management lies in aligning biologic or oral options with patient comorbidities, lifestyle, and insurance coverage.

Omar Noor leads a dynamic discussion on personalized psoriasis therapy, addressing patient challenges and innovative treatment options.

Art Garfunkel raises awareness about psoriasis, sharing his journey and the impact of tildrakizumab treatment in a campaign for support and hope.

Explore the latest advancements in psoriasis treatment with innovative topical therapies, enhancing patient outcomes and simplifying management for diverse skin types.

Pediatric psoriasis poses unique treatment challenges, highlighting the importance of early intervention and awareness of comorbidities in young patients.

New 76-week data reveals guselkumab's significant benefits for plaque psoriasis, enhancing clinical outcomes, improving quality of life, and reducing stigmatization.

New insights reveal that those with low BSA involvement often face significant disease burdens, challenging traditional treatment criteria.

Explore the evolving landscape of moderate psoriasis treatment, emphasizing patient-centered care and innovative therapies for improved quality of life.

Explore the latest advancements in psoriasis treatment, including pediatric care and innovative therapies, during Psoriasis Action Month. Stay informed!

Discover the promising results of ME3183, a novel oral treatment for plaque psoriasis, showing significant efficacy and safety in a recent study.

An expert discusses how successful psoriasis management requires patient-centered care, shared decision-making, matching therapy to individual patient needs rather than just the disease, and ongoing communication to ensure treatment adherence and success.

An expert discusses how treating busy professionals with scalp and nail psoriasis involves addressing injection anxiety, treatment adherence challenges, and the emotional impact of visible disease through health care provider–administered biologics.

An expert how managing psoriasis in active travelers requires considering dosing frequency, insurance transitions from commercial to Medicare coverage, and selecting biologics with longer intervals between treatments.

An expert discusses how treating older patients with psoriasis, such as a 72-year-old retired teacher, requires addressing cognitive decline, dexterity issues, and comorbidities by considering in-office biologic administration and buy-and-bill processes for Medicare accessibility.

O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.

Tina Bhutani, MD, shares vital insights on psoriasis management, sleep's role in dermatology, and new alopecia areata treatments at Elevate-Derm Summer 2025.

Sun Pharma reveals promising phase 3 results for tildrakizumab (Ilumya) in treating PsA, showing significant symptom improvement in patients.

Matthew Zirwas, MD, discusses the complexities of safety analysis in psoriasis clinical trials, advocating for exposure-adjusted incidence rates to enhance risk communication.

Johnson & Johnson submitted an NDA for icotrokinra, a promising new treatment for moderate to severe plaque psoriasis in adults and adolescents.

A retrospective case series found that apremilast induced complete remission in 6 men with treatment-resistant genital psoriasis.

At a recent Dermatology Times Case-Based Roundtable event, David Cotter, MD, PhD, reviewed treatment considerations for older patients with moderate to severe PsO who are candidates for biologic therapy.

The pharmaceutical companies announced an exclusive global license and transfer agreement for the advancement and commercialization of Spevigo.

Spesolimab effectively targets the IL-36 receptor, reducing inflammation and preventing flares in generalized pustular psoriasis, offering new hope for patients.

Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.